<DOC>
	<DOCNO>NCT00006351</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining SCH 66336 gemcitabine may kill tumor cell . PURPOSE : Phase II trial study effectiveness SCH 66336 plus gemcitabine treating patient advance cancer urinary tract .</brief_summary>
	<brief_title>SCH 66336 Plus Gemcitabine Treating Patients With Advanced Cancer Urinary Tract</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility toxicity SCH 66336 gemcitabine patient advance transitional cell carcinoma urinary tract . - Determine time progression objective response rate treatment regimen patient . - Assess pharmacokinetics regimen patient . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 oral SCH 66336 twice day ( start day 2 first course , start day 1 subsequent course ) . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients follow every 8 week disease progression . PROJECTED ACCRUAL : A total 7-31 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic unresectable primary transitional cell carcinoma urinary tract , include bladder , ureter , renal pelvis At least one measurable lesion 20 mm great conventional technique OR 10 mm great spiral CT scan Must receive one ( one ) prior chemotherapy regimen advance metastatic disease No clinical sign brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) Alkaline phosphatase transaminases great 2.5 time ULN ( great 5 time ULN liver metastasis ) Renal : Creatinine great 1.7 mg/dL Cardiovascular : Normal cardiac function No ischemic heart disease within past 6 month Normal 12 lead ECG Other : No prior gastrectomy gastrointestinal disease may impair absorption SCH 66336 No unstable systemic disease No active uncontrolled infection No psychological , familial , sociological , geographical condition would preclude study No prior concurrent malignancy except cone biopsied carcinoma situ cervix adequately treat basal squamous cell skin cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy No prior farnesyl protein transferase inhibitor gemcitabine Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : At least 2 week since prior major surgery Other : No concurrent anticancer agents No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
</DOC>